-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Jim Kelly
Executive Vice President,
Chief Financial Officer and
Treasurer
Chief Financial Officer and
Treasurer
Mr. Kelly is executive vice president, chief financial officer (CFO) and treasurer with responsibility for finance, investor relations and information technology. Prior to joining Novavax, Mr. Kelly held CFO roles with Supernus Pharmaceuticals and Vanda Pharmaceuticals, in addition to key finance roles at MedImmune (now AstraZeneca), Biogen and Aetna. Mr. Kelly earned a Bachelor of Science in Business Administration from the University of Vermont, a Master of Business Administration from Cornell University, and is a Chartered Financial Analyst (CFA®) charterholder.